Leah Lawrence is a journalist at OBR. She specializes in medicine and healthcare, with a focus on medical specialties including hematology, immunology, immunotherapy, and oncology. Leah's work has been featured in numerous publications, including Oncology Nurse Advisor, CURE Media Group, and MedPage Today.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Leah's articles predominantly focus on healthcare and pharmaceuticals, specifically cancer research and treatment. Her coverage heavily relies on citing data, indicating a preference for evidence-based information.
To effectively reach Leah, consider providing pitches backed by robust scientific or clinical data related to the topics she covers. Additionally, offering access to experts in the field who can offer insights into recent studies or developments in cancer research and treatment may be beneficial.
Given that Leah has no specified geographic focus, relevant information from any location would likely be of interest as long as it contributes to advancing knowledge within the areas of cancer research and treatment.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Leah Lawrence
August 2026 The direct oral anticoagulant (DOAC) rivaroxaban appears to be a promising option for breastfeeding mothers in need of postpartum
By: Leah Lawrence
August 2026 Data from a study presented at the International Society on Thrombosis and Haemostasis 2026 Congress highlighted links between
By: Leah Lawrence
August 2026 Adding ianalumab to eltrombopag resulted in rapid and robust responses in adults with primary immune thrombocytopenia (ITP), according
Discover the key highlights and takeaways from the 2026 SOHO Annual Meeting, focusing on advances in hematologic malignancies.
By: Leah Lawrence
Targeted or immunotherapy-based treatments have been added to or have replaced existing standard-of-care regimens across a variety of hematologic malignanc
By: Leah Lawrence
September 2026 Among patients who are assigned to take aspirin only for the secondary prevention of arterial thrombosis, a cancer diagnosis
By: Leah Lawrence
In 2025, the FDA approved the TROP2-directed antibody drug conjugate datopotamab deruxtecan (Dato-DXd) for treatment of patients with unresectable or metastatic, hormone receptor (HR)–positive, HER2-negative breast cancer who had disease progression after prior endocrine-based therapy and chemotherapy. This approval was based on results of the TROPION-Breast01 trial that showed a significant improvement in progression-free survival with Dato-DXd compared with investigator’s choice of chemotherapy (ICC).
By: Leah Lawrence
September 2026 The use of high-dose methotrexate (HD-MTX) as central nervous system (CNS) prophylaxis resulted in no significant reduction
September 2026 The dysfunction of the VWF-ADAMTS13 axis and elevated plasma factor VIII (FVIII) levels may be contributing factors to the
By: Leah Lawrence
The development of immune checkpoint inhibitors, specifically pembrolizumab used alone or in combination with chemotherapy, has improved outcomes for selected patients with triple-negative breast cancer (TNBC). Despite this success, patients still develop primary or acquired resistance.
